Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

@article{Price2013CommentO,
  title={Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".},
  author={Ashleigh R. Price and Guilian Xu and Zoe B. Siemienski and Lisa A. Smithson and David R Borchelt and Todd E Golde and Kevin M. Felsenstein},
  journal={Science},
  year={2013},
  volume={340 6135},
  pages={924-d}
}
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrates short-term bexarotene treatment clearing preexisting β-amyloid deposits from the brains of APP/PS1ΔE9 mice with low amyloid burden, providing a rationale for repurposing this anticancer agent as an Alzheimer's disease (AD) therapeutic. Using a nearly identical treatment regimen, we were unable to detect any evidence of drug efficacy despite demonstration of target engagement. 

From This Paper

Topics from this paper.
12 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…